酪氨酸激酶抑制剂疗法对伴有融合的化疗难治性B细胞前体急性淋巴细胞白血病的疗效 - Suppr

Efficacy of Tyrosine Kinase Inhibitor Therapy in a Chemotherapy-refractory B-cell Precursor Acute Lymphoblastic Leukemia With Fusion.

作者信息

Decool Gauthier, Domenech Carine, Grardel Nathalie, Plesa Adriana, Raczkiewicz Imelda, Ducourneau Benoit, Ruminy Philippe, Pages Marie-Pierre, Girard Sandrine, Fenwarth Laurène, Preudhomme Claude, Bertrand Yves, Duployez Nicolas

机构信息

Laboratory of Hematology, Biology and Pathology Center, CHU Lille, Lille, France.

INSERM UMR-S 1172, Cancer Research Institute, Lille, France.

出版信息

Hemasphere. 2019 Jun 4;3(3):e193. doi: 10.1097/HS9.0000000000000193. eCollection 2019 Jun.

DOI:10.1097/HS9.0000000000000193

PMID:31723830

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6746024/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d7f/6746024/6c55ad155038/hs9-3-e193-g001.jpg

相似文献

Efficacy of Tyrosine Kinase Inhibitor Therapy in a Chemotherapy-refractory B-cell Precursor Acute Lymphoblastic Leukemia With Fusion.酪氨酸激酶抑制剂疗法对伴有融合的化疗难治性B细胞前体急性淋巴细胞白血病的疗效

Hemasphere. 2019 Jun 4;3(3):e193. doi: 10.1097/HS9.0000000000000193. eCollection 2019 Jun.

Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.激酶激活融合和 IKZF1 缺失对儿童高危 B 系急性淋巴细胞白血病的预后影响。

Blood Adv. 2018 Mar 13;2(5):529-533. doi: 10.1182/bloodadvances.2017014704.

BCR-ABL1-like acute lymphoblastic leukaemia: From bench to bedside.BCR-ABL1样急性淋巴细胞白血病：从实验室到临床

Eur J Cancer. 2017 Sep;82:203-218. doi: 10.1016/j.ejca.2017.06.012. Epub 2017 Jul 12.

Identification of an ETV6-ABL2 fusion transcript in combination with an ETV6 point mutation in a T-cell acute lymphoblastic leukaemia cell line.在一株T细胞急性淋巴细胞白血病细胞系中鉴定出一种ETV6-ABL2融合转录本，并伴有ETV6点突变。

Br J Haematol. 2002 Nov;119(2):454-8. doi: 10.1046/j.1365-2141.2002.03850.x.

A Novel Case of ABL2 Chromosomal Rearrangement in High-Risk B-Cell Acute Lymphoblastic Leukemia.高危B细胞急性淋巴细胞白血病中ABL2染色体重排的一例新病例

J Assoc Genet Technol. 2019;45(2):73-76.

T-cell-rich HLA-haploidentical hematopoietic stem cell transplantation for relapsed/refractory pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia without posttransplant tyrosine kinase inhibitor therapy.富含T细胞的HLA单倍型相合造血干细胞移植治疗复发/难治性儿童费城染色体阳性急性淋巴细胞白血病且不进行移植后酪氨酸激酶抑制剂治疗

Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26242. Epub 2016 Oct 26.

RCSD1-ABL2 fusion resulting from a complex chromosomal rearrangement in high-risk B-cell acute lymphoblastic leukemia.高危B细胞急性淋巴细胞白血病中复杂染色体重排导致的RCSD1-ABL2融合。

Leuk Lymphoma. 2015 Apr;56(4):1145-7. doi: 10.3109/10428194.2014.951851. Epub 2014 Aug 26.

Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report.伴有变异型ATF7IP/PDGFRB融合且对酪氨酸激酶抑制剂治疗反应良好的急性淋巴细胞白血病患者：一例报告

Am J Case Rep. 2017 Nov 14;18:1204-1208. doi: 10.12659/ajcr.906300.

Molecular remission using low-dose immunotherapy for relapsed refractory Philadelphia chromosome-positive precursor B-cell acute lymphoblastic leukemia post-allogeneic stem cell transplant.低剂量免疫疗法用于异基因干细胞移植后复发难治性费城染色体阳性前体B细胞急性淋巴细胞白血病的分子缓解。

Future Sci OA. 2019 Apr 12;5(5):FSO380. doi: 10.2144/fsoa-2019-0009. eCollection 2019 Jun.

[Treatment of relapsed or refractory acute lymphoblastic leukemia].[复发性或难治性急性淋巴细胞白血病的治疗]

Rinsho Ketsueki. 2017;58(10):1995-2003. doi: 10.11406/rinketsu.58.1995.

引用本文的文献

Activity of STAMP inhibitors in rearranged acute lymphoblastic leukemia is dependent on the Abl2 SH3 domain.STAMP抑制剂在重排急性淋巴细胞白血病中的活性依赖于Abl2 SH3结构域。

Blood Neoplasia. 2025 Apr 25;2(3):100109. doi: 10.1016/j.bneo.2025.100109. eCollection 2025 Aug.

Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain.ABL 类急性淋巴细胞白血病的酪氨酸激酶抑制剂反应：激酶类型和 SH3 结构域的作用。

Blood. 2024 May 23;143(21):2178-2189. doi: 10.1182/blood.2023023120.

Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in Class Rearrangements.费城样遗传学重排的成人 B 细胞 ALL：对化疗的耐药性和对 Class 重排的酪氨酸激酶抑制剂的反应。

JCO Precis Oncol. 2023 May;7:e2200707. doi: 10.1200/PO.22.00707.

Performances of Targeted RNA Sequencing for the Analysis of Fusion Transcripts, Gene Mutation, and Expression in Hematological Malignancies.靶向RNA测序在血液系统恶性肿瘤中分析融合转录本、基因突变及表达的性能

Hemasphere. 2021 Jan 27;5(2):e522. doi: 10.1097/HS9.0000000000000522. eCollection 2021 Feb.

Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia.胰腺导管腺癌和胰腺癌基质中新兴的激酶治疗靶点。

Int J Mol Sci. 2020 Nov 21;21(22):8823. doi: 10.3390/ijms21228823.

本文引用的文献

Advances in B-cell Precursor Acute Lymphoblastic Leukemia Genomics.B 细胞前体急性淋巴细胞白血病基因组学的进展

Hemasphere. 2018 Jun 20;2(4):e53. doi: 10.1097/HS9.0000000000000053. eCollection 2018 Aug.

Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial.伊马替尼治疗儿童费城染色体阳性急性淋巴细胞白血病（EsPhALL2010）：一项前瞻性、多组、开放标签、单臂临床试验。

Lancet Haematol. 2018 Dec;5(12):e641-e652. doi: 10.1016/S2352-3026(18)30173-X.

BCR-ABL1-like acute lymphoblastic leukaemia: From bench to bedside.BCR-ABL1样急性淋巴细胞白血病：从实验室到临床

Eur J Cancer. 2017 Sep;82:203-218. doi: 10.1016/j.ejca.2017.06.012. Epub 2017 Jul 12.

CD25 Expression in B Lymphoblastic Leukemia/Lymphoma Predicts t(9;22)(q34;q11)/Philadelphia Chromosome Translocation (Ph) and Is Associated With Residual Disease in Ph-Negative Patients.B淋巴母细胞白血病/淋巴瘤中CD25的表达可预测t(9;22)(q34;q11)/费城染色体易位(Ph)，并与Ph阴性患者的残留疾病相关。

Am J Clin Pathol. 2016 Nov 1;146(5):632-638. doi: 10.1093/ajcp/aqw178.

Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia.在小儿 B 细胞前体急性淋巴细胞白血病中鉴定 ETV6-RUNX1 样和 DUX4 重排亚型。

Nat Commun. 2016 Jun 6;7:11790. doi: 10.1038/ncomms11790.

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。

Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.

NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors.NUP214-ABL1融合基因定义了一种罕见的B细胞前体急性淋巴细胞白血病亚型，该亚型可能从酪氨酸激酶抑制剂中获益。

Haematologica. 2016 Apr;101(4):e133-4. doi: 10.3324/haematol.2015.136499. Epub 2015 Dec 17.

Multiplexed targeted sequencing of recurrent fusion genes in acute leukaemia.急性白血病中复发性融合基因的多重靶向测序

Leukemia. 2016 Mar;30(3):757-60. doi: 10.1038/leu.2015.177. Epub 2015 Jul 3.

Poly(ADP-ribose) polymerase-13 and RNA regulation in immunity and cancer.聚（ADP - 核糖）聚合酶 - 13与免疫和癌症中的RNA调控

Trends Mol Med. 2015 Jun;21(6):373-84. doi: 10.1016/j.molmed.2015.03.002. Epub 2015 Apr 4.

Genomics in acute lymphoblastic leukaemia: insights and treatment implications.急性淋巴细胞白血病的基因组学：见解与治疗意义。

Nat Rev Clin Oncol. 2015 Jun;12(6):344-57. doi: 10.1038/nrclinonc.2015.38. Epub 2015 Mar 17.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy of Tyrosine Kinase Inhibitor Therapy in a Chemotherapy-refractory B-cell Precursor Acute Lymphoblastic Leukemia With Fusion.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献